News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

PledPharma receives 500,000 SEK in VINNOVA financing

April 3, 2012

PledPharma AB
Company Announcement

PledPharma receives 500,000 SEK in VINNOVA financing

Vinnova has decided to give PledPharma AB 500,000 SEK in financing from the
“Forska & Väx” (Research & Grow) program. 

Stockholm, 2012-04-03 15:30 CEST (GLOBE NEWSWIRE) -- 

The financing will be used for preclinical studies to widen the PledOx project
to also encompass side-effects during other cancer treatment than colorectal
cancer treatment. 

For further information please contact:

Jacques Näsström, CEO, cell: +46 73 713 0979

About PledPharma

PledPharma is a Swedish specialty pharma company, which develops new treatments
of life threatening diseases. PledPharma currently runs two projects in
clinical development phase II with the patented drug substance class,
PLED-derivatives. The preventive effect of PLED-derivatives on adverse effects
of chemotherapy in colon cancer is examined in one trial. Another trial
investigates the ability of PLED-derivatives to reduce reperfusion injuries in
myocardial infarction patients undergoing percutaneous coronary intervention
(PCI). PLED-derivatives protect the body’s normal cells against oxidative
stress, which is a condition due to overproduction of free oxygen radicals.
PLED-derivatives have in previous pre-clinical trials been shown to protect
against oxidative stress. Moreover, the PLED-derivative mangafodipir protected
against the side effects of chemotherapy in colorectal cancer. PledPharma
(STO:PLED) is listed on NASDAQ OMX First North. Erik Penser Bankaktiebolag is
the Certified Adviser. For more information, please visit



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10